It has landed work with NoBACZ, a spin-out from the University of Cambridge, a new second deal with Nearmedic, and has agreed to run testing for an unnamed Cambridge, Massachusetts biotech.
"We are now continuing to sign additional new virology services contracts with third-party customers,” said Open Orphan chairman Cathal Friel in a statement.
“As such, this is delivering upon one of our key commitments from when we acquired hVIVO earlier this year that, as part of our growth strategy, we were going to expand the range of our service offerings to third party pharmaceutical and biotech companies,“ he added.
NoBACZ is developing an environmentally friendly antimicrobial, antiviral coating that prevents surfaces from being a major source of infection transmission.
It is working with hVIVO at its East London lab to test its products against a range of viruses, including coronaviruses.
It has won a second contract with Nearmedic, this time to support the development of a RegG3 drug as a treatment for COVID-19. This will be followed by the expansion of this product into disease areas such as cystic fibrosis.
Finally, it has inked an agreement to run in vitro testing from its laboratory for the unnamed US biotech company.